Search

Displaying results 231 - 240 of 1777 in total
  1. Drug

    Delafloxacin

    go.drugbank.com/drugs/DB11943
    ApprovedInvestigational

    Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, a...

  2. Drug

    Azithromycin

    go.drugbank.com/drugs/DB00207
    ApprovedInvestigational

    It was initially approved by the FDA in 1991 [A174175].

    Products: Nra-azithromycin
  3. Drug

    Copper

    go.drugbank.com/drugs/DB09130
    ApprovedInvestigational

    It is important to the function of many enzymes including cytochrome c oxidase, monoamine oxidase and superoxide dismutase [FDA Label].

    Mixtures: O-Cal FA multivitamin, O-Cal FA multivitamin
  4. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab.

  5. Drug

    Curcuma xanthorrhiza oil

    go.drugbank.com/drugs/DB11265
    ApprovedNutraceutical

    Curcuma xanthorrhiza oil is extracted from Curcuma xanthorrhiza Roxb., a member of the ginger family (Zingiberaceae) that is widely distributed in the region of Southeastern Asia . Curcuma xanthorrhiza is also known as Javanese Turmeric ...

  6. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    arthritis (RA) in combination with methotrexate. … [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid

  7. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    Within Canada and the United States, paritaprevir is currently available in three fixed dose products: Viekira Pak (FDA), Technivie (FDA and Health Canada), and Holkira Pak (Health Canada). … More specifically, paritaprevir prevents viral replication by inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].

  8. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Ombitasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly [FDA Label]. … Ombutasvir is also available as a fixed-dose combination product with [DB09297] and [DB00503] as the FDA- and Health Canada-approved product Technivie.

  9. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. … [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA

  10. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically